Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.

Abstract

AIMS The purpose of this study is to assess the in vitro enzyme inhibition profile of DSP-7238, a novel non-cyanopyrrolidine dipeptidyl peptidase (DPP) IV inhibitor and to evaluate the acute and chronic effects of this compound on glucose metabolism in two different mouse models of type 2 diabetes. METHODS The in vitro enzyme inhibition profile of DSP… (More)
DOI: 10.1111/j.1463-1326.2009.01180.x

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.